A Randomized, Double-Masked and Placebo-Controlled Study to Evaluate the Efficacy and Safety of Sarilumab Administered Subcutaneously Every 2 Weeks in Patients With Non-Infectious, Intermediate, Posterior or Pan-Uveitis (NIU)

Trial Profile

A Randomized, Double-Masked and Placebo-Controlled Study to Evaluate the Efficacy and Safety of Sarilumab Administered Subcutaneously Every 2 Weeks in Patients With Non-Infectious, Intermediate, Posterior or Pan-Uveitis (NIU)

Completed
Phase of Trial: Phase II

Latest Information Update: 23 Jun 2017

At a glance

  • Drugs Sarilumab (Primary)
  • Indications Uveitis
  • Focus Therapeutic Use
  • Acronyms SARIL-NIU-SATURN; SARILNIUSATURN
  • Sponsors Sanofi
  • Most Recent Events

    • 26 Apr 2016 Status changed from active, no longer recruiting to completed.
    • 08 Jun 2015 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.
    • 13 Apr 2015 According to the ClinicalTrials.gov record, planned end date changed from 1 Sep 2016 to 1 Apr 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top